Agomelatine, a melatonin agonist with antidepressant properties

Bibliography

• Dubovsky SL, Dubovsky AN. Concise guide to mood disorders. Washington, DC: American Psychiatric Press; 2002
   Google Scholar
• Anderson I, Ferrier IN, Baldwin RC, et al. Evidence-based guidelines for treating depressive disorders with antidepressants: a revision of the 2000 British Association for Psychopharmacology Guidelines. J Psychopharmacol 2008;22:343-96
   PubMed Web of Science ®Google Scholar
• Bauer M, Whybrow PC, Angst J, et al. World Federation of Societies of Biological Psychiatry (WFSBP) Task Force on Treatment Guidelines for unipolar depressive disorders. Part 2: maintenance treatment of major depressive disorder and treatment of chronic depressive disorders and subthreshold depression. World J Biol Psychiatry 2002;3:69-86
   PubMedGoogle Scholar
• Krishnan V, Nestler EJ. The molecular neurobiology of depression. Nat Insight 2008;455(7215):894-902
   Google Scholar
• Dubovsky SL. Clinical guide to psychotropic medications. New York: WW Norton; 2005
   Google Scholar
• Coryell W, Endicott J, Keller MB. Predictors of relapse into major depressive disorder in a nonclinical population. Am J Psychiatry 1991;148:1353-8
   PubMed Web of Science ®Google Scholar
• Barbui C, Hotopf M, Freemantle N, et al. Treatment discontinuation with selective serotonin reuptake inhibitors (SSRIs) versus tricyclic antidepressants (TCAs). Cochrane Database Syst Rev 2000;(4):CD002791
   PubMedGoogle Scholar
• Clayton AH, Pradko JF, Croft HA, et al. Prevalence of sexual dysfunction among newer antidepressants. J Clin Psychiatry 2002;63:357-66
   PubMed Web of Science ®Google Scholar
• Gill HS, DeVane CL, Risch SC. Extrapyramidal symptoms associated with cyclic antidepressant treatment: a review of the literature and consolidating hypotheses. J Clin Psychopharmacol 1997;17:377-89
   PubMed Web of Science ®Google Scholar
• Lake MB, Birmaher B, Wassick S, et al. Bleeding and selective serotonin reuptake inhbitors in childhood and adolescence. J Child Adolesc Psychopharmacol 2000;10:35-8
   PubMed Web of Science ®Google Scholar
• Taylor D, Lader M. Cytochromes and psychotropic drug interactions. Br J Psychiatry 1994 1994;168(5):529-32
   Google Scholar
• Millan MJ. Multi-target strategies for the improved treatment of depressive states: conceptual foundations and neuronal substrates, drug discovery and therapeutic application. Pharmacol Ther 2006;110:135-370
   PubMed Web of Science ®Google Scholar
• Hopkins AL. Network pharmacology: the next paradigm in drug discovery. Nat Chem Biol 2008;4:682-90
   PubMed Web of Science ®Google Scholar
• Morphy R, Kay C, Rankovic Z. From magic bullents to designed mujltiple ligands. Drug Discov Today 2004;9:641-52
   PubMed Web of Science ®Google Scholar
• Santarelli L, Saxe M, Gross C, et al. Requirement of hippocampal neurogenesis for the behavioral effects of antidepressants. Science 2003;301:805-9
   PubMed Web of Science ®Google Scholar
• Shelton RC. Intracellular mechanisms of antidepressant drug action. Harv Rev Psychiatry 2000;8:161-74
   PubMed Web of Science ®Google Scholar
• Lader M. Limitations of current medical treatments for depression: disturbed circadian rhythms as a possible therapeutic target. Eur Neuropsychopharmacol 2007;17:743-55
   PubMed Web of Science ®Google Scholar
• Racagni G, Riva MA, Popoli M. The interaction between the internal clock and antidepressant efficacy. Int Clin Psychopharmacol 2007;22(Suppl 2):S9-14
   PubMedGoogle Scholar
• San L, Arranz B. Agomelatine: a novel mechanism of antidepressant action involving the melatonergic and the serotonergic system. Eur Psychiatry 2008;23:396-402
   PubMed Web of Science ®Google Scholar
• Fuchs E, Simon M, Schmelting B. Pharmacology of a new antidepressant: benefit of the implication of the melatonergic system. Int Clin Psychopharmacol 2006;21(Suppl 1):S17-20
   PubMed Web of Science ®Google Scholar
• Lam RW. High-quality remission: potential benefits of the melatonergic approach for patients with major depressive disorder. Int Clin Psychopharmacol 2007;22(Suppl 2):S21-5
   PubMed Web of Science ®Google Scholar
• Zupancic M, Guilleminault C. Agomelatine. A preliminary review of a new antidepressant. CNS Drugs 2006;20:981-92
   PubMed Web of Science ®Google Scholar
• Audinot V, Mailliet F, Lahaye-Brasseur C, et al. New selective actions of human cloned melatonin Mt1 and Mt2 receptors. Naunyn Schmiedebergs Arch Pharmacol 2003;367:553-61
   PubMed Web of Science ®Google Scholar
• Millan MJ, Gobert A, Lejeune F, et al. The novel melatonin agonist agomelatine (S20098) is an antagonist at 5-hydroxytryptamine2C receptors, blockade of which enhances the activity of frontocortical dopaminergic and noradrenergic pathways. J Pharmacol Exp Ther 2003;306:954-64
   PubMed Web of Science ®Google Scholar
• Dolder CR, Nelson M, Snider M. Agomelatine treatment of major depressive disorder. Ann Pharmacother 2008;42:1822-31
   PubMed Web of Science ®Google Scholar
• Van Reeth O, Olivares E, Turek FW, et al. Resynchronisation of a diurnal rodent circadian clock accelerated by a melatonin agonist. Neuroreport 1998;9:1901-5
   PubMed Web of Science ®Google Scholar
• Gressens P, Schwendimann L, Husson I, et al. Agomelatine, a melatonin receptor agonist with 5-HT(2C) receptor antagonist properties, protects the developing murine white matter against excitotoxicity. Eur J Pharmacol 2008;588:58-63
   PubMed Web of Science ®Google Scholar
• Banasr M, Soumier A, Herv M, et al. Agomelatine, a new antidepressant, induces regional changes in hippocampal neurogenesis. Biol Psychiatry 2006;59:1087-96
   PubMed Web of Science ®Google Scholar
• Bertaina-Anglade V, la Rochelle CD, Boyer PA, Mocaer E. Antidepressant-like effects of agomelatine (S 20098) in the learned helplessness model. Behav Pharmacol 2006;17:703-13
   PubMed Web of Science ®Google Scholar
• Loiseau F, Bihan CL, Hamon M, Thiebolt M-H. Effects of melatonin and agomelatine in anxiety-related procedures in rats: interaction with diazepam. Eur Neuropsychopharmacol 2006;16:417-28
   PubMed Web of Science ®Google Scholar
• Stein DJ, Ahokas AA, de Bodinat C. Efficacy of agomelatine in generalized anxiety disorder. A randomized, double-blind, placebo-controlled study. J Clin Psychopharmacol 2008;28:561-6
   PubMed Web of Science ®Google Scholar
• Loo H, Hale D, D'Haenen H. Determination of the dose of agomelatine, a melatoninergic agonist and selective 5-HT(2C) antagonist, in the treatment of major depressive disorder: a placebo-controlled dose range study. Int Clin Psychopharmacol 2002;17:239-47
   PubMed Web of Science ®Google Scholar
• Loo H, Dalery J, Macher J-P, Payen A. Blind pilot study comparing the therapeutic effect of two doses of agomelatine, an agonist of melatonin and antagonist of 5HT(2C) receptors, in 30 patients presenting with a major depressive episode. Encephale 2003;29:165-71
   PubMed Web of Science ®Google Scholar
• Olie JP, Kasper S. Efficacy of agomelatine, a MT1/MT2 receptor agonist with 5-HT-2C antagonistic properties, in major depressive disorder. Int J Neuropsychopharmacol 2007;10:661-73
   PubMed Web of Science ®Google Scholar
• Montgomery S, Kasper S. Severe depression and antidepressants: focus on a pooled analysis of placebo-controlled studies on agomelatine. Int Clin Psychopharmacol 2007;22:283-91
   PubMed Web of Science ®Google Scholar
• Kennedy SH, Rizvi S, Fulton K, Rasmussen J. A double-blind comparison of sexual functioning, antidepressant efficacy, and tolerability between agomelatine and venlafaxine XR. J Clin Psychopharmacol 2008;28:329-33
   PubMed Web of Science ®Google Scholar
• Lemoine P, Guilleminault C, Alvarez E. Improvement in subjective sleep in major depressive disorder with a novel antidepressant, agomelatine: randomized, double-blind comparison with venlafaxine. J Clin Psychiatry 2007;68:1723-32
   PubMed Web of Science ®Google Scholar
• Calabrese J, Guelfi JD, Perdrizet-Chevallier C. Agomelatine adjunctive therapy for acute bipolar depression: preliminary open data. Bipolar Disord 2007;9:628-35
   PubMed Web of Science ®Google Scholar
• Pjrek E, Winkler D, Praschak-Rieder N, Kasper S. Agomelatine in the treatment of seasonal affective disorder. Psychopharmacology 2007;190:575-9
   PubMed Web of Science ®Google Scholar
• Leproult R, Van Onderbergen A, L'Hermite-Baleriaux M, et al. Phase-shifts of 24-h rhythms of hormonal release and body temperature following early eventing administration of the melatonin agonist agomelatine in healthy older men. Clin Endocrinol 2005;63:298-304
   PubMed Web of Science ®Google Scholar
• Salva M-A, Vanier B, Laredo J, et al. Major depressive disorder, sleep EEG and agomelatine: an open-label study. Int J Neuropsychopharmacol 2007;10:691-6
   PubMed Web of Science ®Google Scholar
• Lopes MC, Quera-Salva MA, Guilleminault C. Cyclic alternating pattern in the NREM sleep of patients within major depression disorder: baseline results and change overtime with a new antidepressant: agomelatine. Sleep Med 2005;6(Suppl 2):87-8
   PubMed Web of Science ®Google Scholar
• Montgomery S, Kennedy SH, Burrows GD, et al. Absence of discontinuation symptoms with agomelatine and occurrence of discontinuation with paroxetine: a randomized, double-blind, placebo-controlled discontinuation study. Int Clin Psychopharmacol 2004;19:271-80
   PubMed Web of Science ®Google Scholar
• Golino P, Piscione F, Benedict CR, et al. Local effect of serotonin released during coronary angioplasty. N Engl J Med 1994;330:523-8
   PubMed Web of Science ®Google Scholar
• Kyriakides ZS, Sbarouni E, Antoniadis A, Kremastinos DT. Intracoronary ketanserin augments coronary collateral blood flow and decreases myocardial ischemia during baloon angioplasty. Cardiovasc Drugs Ther 1999;13:415-22
   PubMed Web of Science ®Google Scholar
• Serruys PW, Klein W, Tijssen JP, et al. Evaluation of ketanserin in the prevention of restensosis after percutaneous transluminal coronary angioplasty. A multicenter randomized double-blind placebo-controlled trial. Circulation 1993;88:1588-601
   PubMed Web of Science ®Google Scholar